Jens Atzpodien

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1

Marie Marchand, Nicolas van Baren, P. Weynants et al. · International Journal of Cancer · 1999 · 786 citations

Subcutaneous Injections, Immunology, Immunoediting +20

Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies

Jens Atzpodien · The Lancet · 1990 · 294 citations

Hematological Malignancy, Medicine, Malignant Blood Disorder +9

CXCR4/CXCL12 expression and signalling in kidney cancer

Andres Jan Schrader, Oskar Lechner, Markus F. Templin et al. · British Journal of Cancer · 2002 · 254 citations · Full text

Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Jens Atzpodien, Hartmut Kirchner, Udo Jonas et al. · Journal of Clinical Oncology · 2004 · 224 citations · Full text

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11